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Abstract
Background: Copy number variations play a significant role in the aetiology of developmental disabilities including
non-syndromic intellectual disability and autism.
Case presentation: We describe a 19-year old patient with intellectual disability and autism for whom chromosomal
microarray (CMA) analysis showed the unusual finding of two de novo microdeletions in cis position on chromosome
6q16.1q16.2 and 6q16.3. The two deletions span 10 genes, including FBXL4, POU3F2, PRDM13, CCNC, COQ3 and GRIK2.
We compared phenotypes of patients with similar deletions and looked at the involvement of the genes in neuronal
networks in order to determine the pathogenicity of our patient’s deletions.
Conclusions: We suggest that both deletions on 6q are causing his disease phenotype since they harbour several
genes which are implicated in pathways of neuronal development and function. Further studies regarding the
interaction between PRDM13 and GRIK2 specifically may be interesting.
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Background
Copy number variations (CNV) play a significant role in
the aetiology of developmental disabilities including
non-syndromic intellectual impairment and/or autism
[1–3], accounting for about 10–20% of non-syndromic
patients [1, 4, 5]. In addition, mutations in numerous
genes have been linked to the aetiology of intellectual
disability (ID) [1] and autism spectrum disorders (ASD).
Reduced penetrance and variable expressivity of CNVs
and mutations add to the complexity of interpretation of
causality. Therefore, although known to be highly herit-
able, the aetiology of ASD is still poorly understood with
no single candidate gene accounting for a majority of
ASD susceptibility [6–8]. Interpretation of the clinical
significance of CNVs and evaluation of their contribu-
tion to the phenotype remains challenging, although
CMAs are now widely used for diagnostic purposes.
We report on a patient with global developmental
delay/intellectual disability (DD/ID) and autism for
whom CMA analysis revealed the unusual finding of two
microdeletions on chromosome 6q. Familial segregation
analysis confirmed de novo events and cis-configuration
of both deletions. Phenotype-genotype correlations of all
genes within the deletions allowed to determine a likely
pathogenic contribution of both deletions. Genes within
both deletions are involved in ASD pathways and likely
represent a contiguous gene deletion syndrome.
Case presentation
Our patient, which was last seen at 19 years of age, was
the second of three children of healthy non- consan-
guineous Caucasian parents. The family history was
unremarkable.
He was born at term after an uneventful pregnancy.
Birth measurements were all above the 90th centiles
with weight of 4750 g (>P 90), length of 55 cm (>P90)
and occipitofrontal circumference (OFC) of 37 cm (>P
90). Neonatal and infancy periods were unremarkable.
The boy said his first words at 12 months and walked
unsupportedly at 15 months of age. At age two, macro-
cephaly (above the 97th centiles for OFC) and stagnation
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of expressive speech as well as stereotypic behaviour and
missing eye contact were noted.
At 6 ½ years the boy was diagnosed with infantile
autism and severe intellectual disability. The results
of the autism diagnostic observation schedule (ADOS)
were above the cut-off for autism. In the Vineland
adaptive behaviour scale he showed a severe develop-
mental delay (developmental quotient 30); his social
behaviour and communication behaviour met the
level of a 1 ½ year old, and everyday life skills levels
were comparable with a 2 ½ year old child. The boy
had a very short attention span, showed stereotypic
behaviour, hardly no functional or symbolic playing,
almost no eye contact and minimal adaptive social
skills. Expressive and receptive language skills were
limited to simple orders.
Further regular follow-up exams at different ages
confirmed the clinical findings. Except for a mild
hypotonia neurological exams were in normal range.
The patient developed dog phobia. No aggressivity or
autoaggressivity was noted. Access to specialized
school education and therapies as well as a stimulat-
ing familial environment allowed a certain independ-
ence in these surroundings. The patient today is able
to ride a bicycle and swim. He still needs help with
body hygiene.
At the last clinical exam at age 19 dysmorphic signs
were a mild dolichocephalus, a low set hairline on the
neck, a broad face, hypertelorism (IPD > 97 P), medial
sparse eyebrows, bilateral prominent anthelices, poster-
iorly rotated ears, a short wide nose, full lips, widely
spaced teeth, prominent upper incisors, long hands
(hand length >97 P), hyperextensible joints and a slight
funnel chest. Measurements taken for OFC, weight and
length were above the 97th centile. The parents and sib-
lings physical parameters are the following: mother
167 cm, 64 kg (BMI 22.9 kg/m2), father 187 cm, 98 kg
(BMI 28 kg/m2), sister 1 and 2 174 cm, 58 kg (BMI
19.2 kg/m2) and 179 cm, 65 kg (BMI 20.3 kg/m2),
respectively.
Apart from frequent middle ear infections the pa-
tient was in good health. Extensive investigations in
childhood which included brain magnetic resonance
imaging (MRI), cranial computed tomography (CT),
electroencephalogram and an abdominal ultrasound
all proved unobtrusive. An X-ray of the hand per-
formed at age 10 showed a slightly retarded bone
age. Conventional chromosome analysis of lympho-
cytes (GTG-banding, 450 band level) did not show
any numerical or structural anomalies. Specific test-
ing for Fragile – X syndrome, Prader-Willi-, Angel-
man- and Beckwith-Wiedemann syndromes and for




Array genomic hybridization of DNA from peripheral
blood lymphocytes was performed in the patient and
both his parents, using the NimbleGen WG HG18
Tiling 385 K CGHv.2.0 array. The tiling array version
2.0 contains 385,000 probes with a probe spacing of
6000 bp. Labelling and hybridization of test and refer-
ence DNA was performed according to manufacturer’s
protocols.
The analysis identified two deletions in 6q separated
by a segment of 2 Mb. The proximal deletion (Deletion
Nr.1) (Fig. 1) is an interstitial deletion localized in the
chromosomal region 6q16.1q16.2, spanning ~1.4 Mb
(chr6: 98,693,279-100,083,279 bp, hg19 build) and
encompassing nine protein coding genes of which five
are listed in the Online Mendelian Inheritance in Man
(OMIM) database (Table 2).
The distal deletion (Deletion Nr.2), (Fig. 2) also
an interstitial deletion, spans 760 kb and was
assigned to the 6q16.3 chromosomal region (chr6:
102,113,307-102,873,307 bp, hg19 build). Its proximal
breakpoint disrupts the GRIK2 gene in exon 3; cod-
ing exons 4–16 are therefore deleted. Results are
shown in Fig. 3.
Fluorescence in situ hybridization
To further investigate the structural anomaly
fluorescence-in-situ-hybridization (FISH) using the
BlueGnome probes RP11-758C21 for 6q16.2 (green)
and RP11-487 F5 for 6q16.3 (red) was done in the pa-
tient and his parents. The deletions were confirmed to
be in cis-position in the patient. FISH analysis of the
parents showed both loci to be present in correct pos-
ition and orientation which proved a de novo origin of
the deletions in the patient. There was no evidence for
a complex structural rearrangement in the parents.
FISH results are shown in Fig. 4.
Sanger sequencing of GRIK2
Because bi-allelic mutations in GRIK2 have been shown
to cause autosomal recessive intellectual disability [9],
we sequenced all 16 exons of the GRIK2 gene including
exon-intron boundaries to confirm or rule out a com-
pound heterozygous mutation on the second allele in
GRIK2. No mutation was identified. Primer sequences
can be obtained upon request.
Genotype-phenotype correlations
We searched current databases, specifically Decipher
[10], ClinGen [11] and DGV [12] for overlapping
copy number variations in patients or healthy individ-
uals. Results of the overlapping pathogenic deletions
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are shown in Table 1. We performed an extended lit-
erature and database search on all genes included in
the deleted regions, their functions and related phe-
notypes using PubMed [13] and OMIM [14]. Results
are summarized in Table 2.
Discussion
Chromosomal microarray is now widely used as a diag-
nostic tool to elucidate the aetiology of developmental
delay, intellectual disability and autism spectrum disor-
ders. The genetic heterogeneity, reduced penetrance and
Fig. 1 UCSC genome browser, chromosomal region 6q16.1q16.3. The black bar marked “Patient del. Nr. 1” shows the proximal deletion of our
patient, the other black bars patients with overlapping deletions as described in Table 1. RefSeq genes are depicted in blue
Fig. 2 UCSC genome browser, chromosomal region 6q16.2q16.3. The black bar marked „Patient del. Nr.2“ shows the distal deletion of our patient,
other black bars patients with overlapping or flanking deletions as described in Table 1. RefSeq genes are depicted in blue
Strunk et al. Molecular Cytogenetics  (2016) 9:88 Page 3 of 8
variable expressivity as well as suggested polygenic
versus monogenic inheritance often renders the inter-
pretation of the causal contribution of single rare CNVs
to these phenotypes difficult. Here, we report on a now
adult patient with global developmental delay/intellec-
tual disability and autism for which CMA analysis
has revealed the unusual finding of two interstitial
de novo microdeletions in cis-position on chromo-
some 6q. Both deletions, spanning ~1.39 Mb and
~0.7 Mb respectively, separated by a genomic seg-
ment of ~2 Mb, have not been described before, but
phenotype-genotype correlations with overlapping
deletions mentioned in the medical literature and da-
tabases as well as haploinsufficiency of genes part of
neuronal networks encompassed in both deletions,
likely suggest their pathogenic contribution. Notably,
Kasher et al. reported on several small heterozygous
deletions in 6q16.1 presenting with variable develop-
mental delay, intellectual disability and susceptibility
to obesity. In one of their patients the deletion of
1.04 Mb includes the same nine genes as does the de-
letion Nr. 1 in the patient we describe [15]. The au-
thors suggest a common critical region in their
patients encompassing POU3F2.
Fig. 4 Fluorescence- in-situ-hybridization (FISH) on metaphase spreads of the patient and his parents’ chromosomes 6. We used the locus-specific
Bluegnome probes RP11-758C21 for 6q16.2 (green), targeting deletion Nr 1, and RP11-487 F5 for 6q16.3 (red), targeting deletion nr.2, and the
Abbott centromere specific probe cep 6 (aqua) for control. a Patient, b Patient’s father, c Patient’s mother: Both loci are present in correct
orientation in the parent’s FISH analysis and proved a de novo origin of the deletions in the patient. Deletions in the patient are in cis position
Fig. 3 Array plot of chromosome 6q. Deletion Nr. 1 is on 6q16.1q16.2 (chr6:98693279–100083279 bp); Deletion Nr. 2 on 6q16.3 (chr6:102113307–
102873307 bp). Hg version 19 (GRCh37/hg19)
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POU3F2/Brn2 belongs to a family of transcription
factors that share a highly homologous POU domain
and is highly expressed in the central nervous system
[16], especially the human hypothalamus and hippocam-
pus [15]. POU3F2 upregulates proneuronal genes [16],
promotes neurogenesis in the neocortex and is required
for cortical neural migration [17]. Kasher et al. showed
that in zebrafish, POU3F2 functions as a downstream
target of SIM1 in the leptin – melanocortin – SIM1
pathway and plays a role in the regulation of oxytocin
expression in the hypothalamus. They suggest POU3F2
being the likely causal mechanism affecting hypothal-
amic functions such as the control of food intake and
social behaviour or learning, compatible with the human
phenotypes in 6q16.1 deletions [15].
Previously, Bonaglia et al. [18], Griswold et al. [5], El
Khattabi el al. [19] and Le Caignec et al. [20] reported
on patients with mostly larger heterozygous deletions in
6q16 (in a range between 1.7 and 14 Mb) which do not
allow specific phenotype-genotype correlations. How-
ever, their patients, the patients summarized in Table 1
and our patient share phenotypic findings such as hypo-
tonia, intellectual disability, developmental delay as well
as autistic features or behavioural anomalies reminiscent
of ASD. Macrocephaly and tall stature and/or obesity
are shared physical findings in some patients compatible
Table 1 Overlapping deletions
Decipher ID Variant Interval (Mb) Phenotypes
Overlapping deletion Nr. 1
Our patient loss:
6:98693279–100083279
1.39 posterior rotated ears, macrocephaly, autism,
intellectual disability, speech impairment, hypertelorism,
264111 loss:
6:98966910–101858361




3.43 abnormality of body height, abnormality of the ear,
abnormality of the nasal bridge, behavioural/psychiatric
abnormality, cognitive impairment, high forehead,











(Variant Call ID: nssv578123)
loss:
6:99116405–101714826
2.59 global developmental delay
292356 loss:
6:98905933–100642867
1.37 development delay, learning disabilities, behavioural




1 neonatal hypotonia, mild motor delay, moderate learning
disability, speech delay, very severe obesity (BMI 47),
hyperphagia, behavioural problems [14]
273148 loss:
6:99156238–100644046
1.49 severe intellectual disability, lipoma of the CNS, round





0.7 posterior rotated ears, macrocephaly, autism, intellectual





0.6 global developmental delay
275474 loss:
6:100382250–102582366
2.2 perinatal hypotonia, developmental delay, learning
disabilities, behavioural disorders, hyperphagia, obesity,




Flanking deletion Nr. 2
291845 loss:
6:101962579–102060754
0.1 autism, moderate global developmental delay
Deletions spanning ≤3.5 Mb with a specified phenotype overlapping or flanking with the deletion in our patient as mentioned in the Decipher
(decipher.sanger.ac.uk/browser) and ClinGen (www.clinicalgenome.org/data-sharing/) databases as well as referenced in the medical literature
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with a contribution of the genomic region to growth
regulation. El Khattabi et al. suggested an involvement
of the MCHR2 and SIM1 genes in behavioural disorders
and SIM1 in obesity [19]. Both genes are not located
within the deleted region of our patient. The normal
BMI and feeding habits in our patient are in keeping
with the finding of an incomplete obesity phenotype in
the cohort of El Khattabi et al.
Of further interest, each of the two deletions in our
patient span genes which have been described to play a
significant role in the pathogenesis of autism [5, 6, 18,
21] and intellectual disability [22] due to their common
roles in ASD associated pathways (Table 2). Particularly,
the genes GRIK2, disrupted and partially deleted by
deletion 2 in our patient, and PRDM13, encompassed by
deletion 1, are functionally linked.
Barbon and co-workers showed experimental evidence
that several different splicing variants exist, and splicing
mechanisms lead to truncated subunit isoforms suggest-
ing a complex GluR system [23]. Zhawar et al. found
GluR6 receptor subunits to be differentially expressed
with expression of the GluR6A variant specifically in
brain [24]. Studies on mice lacking the GluK2 subunit of
kainate receptors, for which GRIK2 encodes, observed
reduced social interaction and altered executive func-
tions. The homozygous knockout of the GRIK2 gene
produces a lower capacity for pattern separation and an
increased propensity for pattern completion [8]. Patients
with homozygous mutations in GRIK2 present with auto-
somal recessive intellectual disability [22]. In addition,
studies on CNVs in ASD phenotypes suggest a
contributory role of GRIK2 haploinsufficiency in ASD
Table 2 Involved genes
Chromosome Gene/OMIM
number
Patient phenotype Gene function Resource Mendelian inheritance
Deletion Nr. 1
6 FBXL4/605654 mtDNA depletion syndrome
(infantile encephalomyopathic
type)
Coding for a member of the F-Box family





6 POU3F2/600494 None described POU domain transcription factor
predominantly expressed in the CNS.
Likely playing an important role in
mammalian neurogenesis and neuronal
migration in the neocortex, positive
regulator of Schwann cell development,
downstream target of SIM1
%HI score 15.18
[15–17, 34] Unknown




Prdm transcription factor, neural specific
direct target of Ptf1a, controlling balance
of inhibitory and excitatory neurons in
somatosensory circuits during neuronal
development,
Required to produce the right number
of pax2+ neurons in the dorsal spinal cord
by repressing excitatory cell fate
%HI score 56.20
[25, 35, 36] dominant for NCMD,
otherwise unknown
6 CCNC/123838 None described Member of the cyclin family,
Protein kinase in the RNA polymerase II
complex, cell cycle regulator
%HI score 2.44





6 COQ3/605196 None described Encodes an O-Methyltransferase, involved









Encodes for the glutamate receptor 6,
excitatory neurotransmission in the brain
%HI score 2.34
[5, 6, 9, 18, 22, 39] recessive;
susceptibility gene
Deletion 1 of our patient encompasses 9 genes, including FBXL4, POU3F2, CCNC, USP45, PNISR, FAXC, TSTD3, COQ3 and PRDM13. Deletion 2 partially encompasses
GRIK2 (details see text). In this table only genes are listed with a known function described in OMIM (www.omim.org) or PubMed (http://www.ncbi.nlm.nih.gov/
pubmed). Haploinsufficiency score (%HI) is mentioned as given in the Decipher database. HI score: predicted probability of exhibiting haploinsufficiency. High
ranks 0–10% more likely to exhibit haploinsufficiency, low ranks 90–100% [40]
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[5, 18, 20, 21]. The small size of the deletion reported
by Griswold et al. supports the hypothesis of GRIK2
being a candidate gene for ASD.
GRIK2 is linked to the expression of PRDM13, a gene
involved in neuronal development. PRDM13, a tran-
scription factor, is a critical component in neuronal di-
versity and balance of inhibitory and exhibitory neurons
in the dorsal spinal cord [25]. Most interestingly, cells of
the inhibitory neuronal lineage in the dorsal spinal cord
express excitatory receptor genes/subunits, among them
GRIK2, indicating an interaction between excitatory and
inhibitory neurons [26] (Fig. 5).
Based on these findings haploinsufficiency of all three
genes POU3F2, GRIK2 and PRDM13 indicate a contri-
bution of both deletions to our patient’s phenotype and
suggest their functional interaction as part of a contigu-
ous gene deletion syndrome. However, the specific con-
tribution of PRDM13 to human disease phenotypes
remains to be further elucidated.
Griswold et al. identified several novel candidate
genes in molecular pathways or genetic networks im-
plicated in autism aetiology in a large genome-wide
SNP array in a European ancestry case–control data
set [5]. ASD candidate genes and their functional in-
teractions are tightly linked with general dysregulation
of gene expression, disturbances of neuronal matur-
ation and pattering and may be key in conferring
susceptibility to autism spectrum conditions [27].
Multi-dimensional co-expression analysis of ASD can-
didate genes in the normal developing human brain
suggests the heterogeneous set of ASD candidates to
share transcriptional networks related to synapse
formation and elimination, protein turnover, and mito-
chondrial function [28]. The majority of genes encom-
passed in deletion Nr.1 (Table 2), in particular FBXL4,
CCNC, POU3F2, PRDM13 and COQ3, can be considered
part of these networks [16, 17, 25, 26, 29–31].
Conclusions
Recent research into gene interaction and networks in
autism spectrum disorders and intellectual disability sug-
gest that phenotype-related gene products are integral to
neuronal development. It often remains difficult to draw
firm conclusions as to the pathogenic contribution of
each single CNV or mutation of these genes. However,
we suggest that the two neighbouring deletions on 6q in
our patient are likely to cause his ID/ASD phenotype
since they harbour several genes implicated in different
linked pathways of neuronal development and function.
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Fig. 5 In the dorsal spinal cord PRDM13 is required to produce the correct number of pax2+/GABAergic neurons [25]. Excitatory and inhibitory
neurons of the dorsal spinal cord emerge from progenitor populations within the dorsal neural tube. Depending on the transcription factors that are
expressed progenitors can become neurons in either class. To redirect cell fate such a transcription factor activates lineage specific gene expression of
one lineage and represses the expression of genes in the alternate lineage. The inhibitory (GABAergic) lineage of neurons for example is specified by
the homeodomain (HD) transcription factor Pax2. Pax2 and PRDM13 are required for the specification of inhibitory cell fate in the dorsal spinal cord
and are direct downstream targets of Ptf1a. The excitatory (glutamatergic) lineage is specified by the HD factors Tlx1/3. PRDM13 actively represses
excitatory cell fate by binding to regulatory sequences near Tlx1/Tlx3 genes, suppressing their expression. Ptf1a, a transcription activator induces factor
Pax2 while suppressing the expression of Tlx1/3 which leads – through PRDM13- to an increase of inhibitory neurons at the expense of excitatory
neurons. Adapted from Guo et al. [26] and Chang et al. [25]
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